NCT06502548 Endometriosis Transcriptomic Cell Atlas
| NCT ID | NCT06502548 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Toulouse |
| Condition | Endometriosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 92 participants |
| Start Date | 2024-09-27 |
| Primary Completion | 2027-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 92 participants in total. It began in 2024-09-27 with a primary completion date of 2027-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Endometriosis is an estrogen-dependent, chronic inflammatory gynecologic disease affecting women of reproductive age, with a therapeutic wandering of 6 to 10 years. A better understanding of the initiation phase is a major challenge to improve diagnosis and treatment. The most widely accepted hypothesis to explain the formation of endometriotic lesions is the tubal retrograde reflux during menstruation. However, only 10% of the reproductive age women will develop endometriosis while 90% of women experience retrograde menstruation. This raises the question of the stem cells present in the endometrium and menstrual reflux of these patients, but also of both the peritoneal microenvironment and the estrogenic local signaling which allow the implantation of these lesions.
Eligibility Criteria
Inclusion Criteria: * Patients over 18 and under 45 years of age * Patients with multiple endometriosis sites (superficial, deep and endometriomas) with an indication for surgery to treat disabling painful symptoms and stage III or IV endometriosis in the context of infertility. * Healthy patients including those operated on between the ages of 18 and 45 for tubal ligation * Healthy patients operated on between the ages of 18 and 45 for hysterectomies for benign causes other than endometriosis or adenomyosis * Patients operated on strictly at the time of menstruation * Participants who have not been on hormonal treatment for 2 months * Participant having signed the free and informed consent form * Membership of a Social Security scheme or equivalent Exclusion Criteria: * Patients with endometriosis non-surgically treated * Patients with endometriosis receiving hormonal treatment at the time of surgery or having received hormonal treatment in the 2 months prior to surgery * Patients with adenomyosis only * Healthy non-endometriotic patients undergoing hysterectomy for infectious or malignant causes * Patients benefiting from a legal protection measure (guardianship, curatorship, safeguard of justice) * Patients with positive serology for human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV), hepatitis B (HBV) and hepatitis C (HCV)
Contact & Investigator
Elodie CHANTALAT, MD
PRINCIPAL INVESTIGATOR
University Hospital, Toulouse
Frequently Asked Questions
Who can join the NCT06502548 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 45 Years, studying Endometriosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06502548 currently recruiting?
Yes, NCT06502548 is actively recruiting participants. Contact the research team at chantalat.e@chu-toulouse.fr for enrollment information.
Where is the NCT06502548 trial being conducted?
This trial is being conducted at Toulouse, France.
Who is sponsoring the NCT06502548 clinical trial?
NCT06502548 is sponsored by University Hospital, Toulouse. The principal investigator is Elodie CHANTALAT, MD at University Hospital, Toulouse. The trial plans to enroll 92 participants.